Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-10-17

FDA Approved: VYVGART — Supplemental Application (argenx US)

View source ↗

Summary

The FDA approved a supplemental application for Vyvgart (efgartigimod alfa) submitted by argenx US.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • VYVGART (EFGARTIGIMOD ALFA)

Snippet

SUPPL AP for VYVGART (EFGARTIGIMOD ALFA)